Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to the therapeutic impact

Tohru Utsunomiya, Mitsuo Shimada, Masatoshi Kudo, Takafumi Ichida, Osamu Matsui, Namiki Izumi, Yutaka Matsuyama, Michiie Sakamoto, Osamu Nakashima, Yonson Ku, Norihiro Kokudo, Masatoshi Makuuchi

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

OBJECTIVE:: To examine the prognostic factors and outcomes after several types of treatments in patients with hepatocellular carcinoma (HCC) negative for hepatitis B surface antigen and hepatitis C antibody, so-called "non-B non-C HCC" using the data of a nationwide survey. BACKGROUND:: The proportion of non-B non-C HCC is rapidly increasing in Japan. METHODS:: A total of 4741 patients with non-B non-C HCC, who underwent hepatic resection (HR, n = 2872), radiofrequency ablation (RFA, n = 432), and transcatheter arterial chemoembolization (TACE, n = 1437) as the initial treatment, were enrolled in this study. The exclusion criteria included extrahepatic metastases and/or Child-Pugh C. Significant prognostic variables determined by a univariate analysis were subjected to a multivariate analysis using a Cox proportional hazard regression model. RESULTS:: The degree of liver damage in the HR group was significantly lower than that in the RFA and TACE groups. The HR and TACE groups had significantly more advanced HCC than the RFA group. The 5-year survival rates after HR, RFA, and TACE were 66%, 49%, and 32%, respectively. Stratifying the survival rates, according to the TNM stage and the Japan Integrated Staging (JIS) score, showed the HR group to have a significantly better prognosis than the RFA group in the stage II and in the JIS scores "1" and "2." The multivariate analysis showed 12 independent prognostic factors. HR offers significant prognostic advantages over TACE and RFA. CONCLUSIONS:: The findings of this large prospective cohort study indicated that HR may be recommended, especially in patients with TNM stage II and JIS scores "1" and "2" of non-B non-C HCC.

Original languageEnglish
Pages (from-to)336-345
Number of pages10
JournalAnnals of Surgery
Volume259
Issue number2
DOIs
Publication statusPublished - 2014 Feb

Fingerprint

Hepatocellular Carcinoma
Japan
Therapeutics
Multivariate Analysis
Survival Rate
Hepatitis C Antibodies
Liver
Hepatitis B Surface Antigens
Proportional Hazards Models
Cohort Studies
Prospective Studies
Neoplasm Metastasis

Keywords

  • hepatectomy
  • nationwide survey
  • non-B non-C
  • prognostic factor
  • radiofrequency ablation
  • transarterial chemoembolization

ASJC Scopus subject areas

  • Surgery

Cite this

Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to the therapeutic impact. / Utsunomiya, Tohru; Shimada, Mitsuo; Kudo, Masatoshi; Ichida, Takafumi; Matsui, Osamu; Izumi, Namiki; Matsuyama, Yutaka; Sakamoto, Michiie; Nakashima, Osamu; Ku, Yonson; Kokudo, Norihiro; Makuuchi, Masatoshi.

In: Annals of Surgery, Vol. 259, No. 2, 02.2014, p. 336-345.

Research output: Contribution to journalArticle

Utsunomiya, T, Shimada, M, Kudo, M, Ichida, T, Matsui, O, Izumi, N, Matsuyama, Y, Sakamoto, M, Nakashima, O, Ku, Y, Kokudo, N & Makuuchi, M 2014, 'Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to the therapeutic impact', Annals of Surgery, vol. 259, no. 2, pp. 336-345. https://doi.org/10.1097/SLA.0b013e31829291e9
Utsunomiya, Tohru ; Shimada, Mitsuo ; Kudo, Masatoshi ; Ichida, Takafumi ; Matsui, Osamu ; Izumi, Namiki ; Matsuyama, Yutaka ; Sakamoto, Michiie ; Nakashima, Osamu ; Ku, Yonson ; Kokudo, Norihiro ; Makuuchi, Masatoshi. / Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to the therapeutic impact. In: Annals of Surgery. 2014 ; Vol. 259, No. 2. pp. 336-345.
@article{d263308f833141eb9e74543d543068db,
title = "Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to the therapeutic impact",
abstract = "OBJECTIVE:: To examine the prognostic factors and outcomes after several types of treatments in patients with hepatocellular carcinoma (HCC) negative for hepatitis B surface antigen and hepatitis C antibody, so-called {"}non-B non-C HCC{"} using the data of a nationwide survey. BACKGROUND:: The proportion of non-B non-C HCC is rapidly increasing in Japan. METHODS:: A total of 4741 patients with non-B non-C HCC, who underwent hepatic resection (HR, n = 2872), radiofrequency ablation (RFA, n = 432), and transcatheter arterial chemoembolization (TACE, n = 1437) as the initial treatment, were enrolled in this study. The exclusion criteria included extrahepatic metastases and/or Child-Pugh C. Significant prognostic variables determined by a univariate analysis were subjected to a multivariate analysis using a Cox proportional hazard regression model. RESULTS:: The degree of liver damage in the HR group was significantly lower than that in the RFA and TACE groups. The HR and TACE groups had significantly more advanced HCC than the RFA group. The 5-year survival rates after HR, RFA, and TACE were 66{\%}, 49{\%}, and 32{\%}, respectively. Stratifying the survival rates, according to the TNM stage and the Japan Integrated Staging (JIS) score, showed the HR group to have a significantly better prognosis than the RFA group in the stage II and in the JIS scores {"}1{"} and {"}2.{"} The multivariate analysis showed 12 independent prognostic factors. HR offers significant prognostic advantages over TACE and RFA. CONCLUSIONS:: The findings of this large prospective cohort study indicated that HR may be recommended, especially in patients with TNM stage II and JIS scores {"}1{"} and {"}2{"} of non-B non-C HCC.",
keywords = "hepatectomy, nationwide survey, non-B non-C, prognostic factor, radiofrequency ablation, transarterial chemoembolization",
author = "Tohru Utsunomiya and Mitsuo Shimada and Masatoshi Kudo and Takafumi Ichida and Osamu Matsui and Namiki Izumi and Yutaka Matsuyama and Michiie Sakamoto and Osamu Nakashima and Yonson Ku and Norihiro Kokudo and Masatoshi Makuuchi",
year = "2014",
month = "2",
doi = "10.1097/SLA.0b013e31829291e9",
language = "English",
volume = "259",
pages = "336--345",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to the therapeutic impact

AU - Utsunomiya, Tohru

AU - Shimada, Mitsuo

AU - Kudo, Masatoshi

AU - Ichida, Takafumi

AU - Matsui, Osamu

AU - Izumi, Namiki

AU - Matsuyama, Yutaka

AU - Sakamoto, Michiie

AU - Nakashima, Osamu

AU - Ku, Yonson

AU - Kokudo, Norihiro

AU - Makuuchi, Masatoshi

PY - 2014/2

Y1 - 2014/2

N2 - OBJECTIVE:: To examine the prognostic factors and outcomes after several types of treatments in patients with hepatocellular carcinoma (HCC) negative for hepatitis B surface antigen and hepatitis C antibody, so-called "non-B non-C HCC" using the data of a nationwide survey. BACKGROUND:: The proportion of non-B non-C HCC is rapidly increasing in Japan. METHODS:: A total of 4741 patients with non-B non-C HCC, who underwent hepatic resection (HR, n = 2872), radiofrequency ablation (RFA, n = 432), and transcatheter arterial chemoembolization (TACE, n = 1437) as the initial treatment, were enrolled in this study. The exclusion criteria included extrahepatic metastases and/or Child-Pugh C. Significant prognostic variables determined by a univariate analysis were subjected to a multivariate analysis using a Cox proportional hazard regression model. RESULTS:: The degree of liver damage in the HR group was significantly lower than that in the RFA and TACE groups. The HR and TACE groups had significantly more advanced HCC than the RFA group. The 5-year survival rates after HR, RFA, and TACE were 66%, 49%, and 32%, respectively. Stratifying the survival rates, according to the TNM stage and the Japan Integrated Staging (JIS) score, showed the HR group to have a significantly better prognosis than the RFA group in the stage II and in the JIS scores "1" and "2." The multivariate analysis showed 12 independent prognostic factors. HR offers significant prognostic advantages over TACE and RFA. CONCLUSIONS:: The findings of this large prospective cohort study indicated that HR may be recommended, especially in patients with TNM stage II and JIS scores "1" and "2" of non-B non-C HCC.

AB - OBJECTIVE:: To examine the prognostic factors and outcomes after several types of treatments in patients with hepatocellular carcinoma (HCC) negative for hepatitis B surface antigen and hepatitis C antibody, so-called "non-B non-C HCC" using the data of a nationwide survey. BACKGROUND:: The proportion of non-B non-C HCC is rapidly increasing in Japan. METHODS:: A total of 4741 patients with non-B non-C HCC, who underwent hepatic resection (HR, n = 2872), radiofrequency ablation (RFA, n = 432), and transcatheter arterial chemoembolization (TACE, n = 1437) as the initial treatment, were enrolled in this study. The exclusion criteria included extrahepatic metastases and/or Child-Pugh C. Significant prognostic variables determined by a univariate analysis were subjected to a multivariate analysis using a Cox proportional hazard regression model. RESULTS:: The degree of liver damage in the HR group was significantly lower than that in the RFA and TACE groups. The HR and TACE groups had significantly more advanced HCC than the RFA group. The 5-year survival rates after HR, RFA, and TACE were 66%, 49%, and 32%, respectively. Stratifying the survival rates, according to the TNM stage and the Japan Integrated Staging (JIS) score, showed the HR group to have a significantly better prognosis than the RFA group in the stage II and in the JIS scores "1" and "2." The multivariate analysis showed 12 independent prognostic factors. HR offers significant prognostic advantages over TACE and RFA. CONCLUSIONS:: The findings of this large prospective cohort study indicated that HR may be recommended, especially in patients with TNM stage II and JIS scores "1" and "2" of non-B non-C HCC.

KW - hepatectomy

KW - nationwide survey

KW - non-B non-C

KW - prognostic factor

KW - radiofrequency ablation

KW - transarterial chemoembolization

UR - http://www.scopus.com/inward/record.url?scp=84892926926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892926926&partnerID=8YFLogxK

U2 - 10.1097/SLA.0b013e31829291e9

DO - 10.1097/SLA.0b013e31829291e9

M3 - Article

AN - SCOPUS:84892926926

VL - 259

SP - 336

EP - 345

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 2

ER -